Business, Health Care

Merck and Hanmi Pharmaceutical enter into licensing agreement to develop Efinopegdutide, an investigational once-weekly therapy for nonalcoholic steatohepatitis (NASH)

Michelle Dryden Comments Off on Merck and Hanmi Pharmaceutical enter into licensing agreement to develop Efinopegdutide, an investigational once-weekly therapy for nonalcoholic steatohepatitis (NASH)

KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Hanmi Pharmaceutical today announced that the companies have entered into an exclusive licensing agreement for the development, manufacture and commercialization of efinopegdutide (formerly HM12525A), Hanmi’s investigational

Business

Hudson reports second quarter 2020 results

Reopened Over 200 Stores To-Date in Phased Approach Reduction in Force Implemented to Help Offset Impact of Reduced Traveler Volumes EAST RUTHERFORD, N.J.–(BUSINESS WIRE)–Hudson (NYSE: HUD), a North American travel experience leader with more than 1,000 stores in airports, commuter hubs, landmarks

Business

SHI named one of Forbes’ Best Employers for Women 2020

SOMERSET, N.J.–(BUSINESS WIRE)–SHI International, one of North America’s largest IT solutions providers, has been recognized on Forbes’ list of America’s Best Employers for Women 2020. Presented by Forbes and Statista Inc., the awards list is based on an independent survey of over

Business

AM Best assigns Issuer Credit Rating to LRG (US), Inc.

OLDWICK, N.J.–(BUSINESS WIRE)–AM Best has assigned a Long-Term Issuer Credit Rating of “a” to LRG (US), Inc. (Delaware). The outlook assigned to this Credit Rating (rating) is stable. LRG (US), Inc. is the intermediate holding company of London Life International Reinsurance Corporation

Business

Church & Dwight reports Q2 results

2020 Second Quarter Results Sales growth +10.6%: Dom. +13.6%; Int’l +0.5%; SPD +3.0% Organic sales +8.4%: Dom. +10.7%; Int’l +0.6%; SPD +3.0% Gross Margin +220 bps. to 46.8% EPS +36.4%; Adjusted EPS +35.1% YTD Cash from Operations +70%; Ex tax deferral +47%